I was in
The biggest risks come from improper technique, not the vitamin itself
Regulatory decisions regarding GLP-1 agonists reflect the ongoing dialogue between pharmaceutical companies, regulatory agencies, and the medical community to ensure the availability of safe and effective treatment options for patients in need
And as you know, theyve created these subsidiary companies called GPOs, where they have the GPO, who, in two out of three cases is based offshore, and that company negotiates with the manufacturer, and then the GPO, after getting a price with the manufacturer, then negotiates with the PBM but keeps part of the profits themselves, so that the GPO retains profits, and that gives the PBM the plausible deniability to employers to say, Oh no, we pass through our entire rebate when, in reality, they dont
J Clin Endocrinol Metab (2016) 101(3):11819